The Ink4b gene (Cdkn2b) encodes p15
Introduction
The Ink4 family of D cyclin-dependent kinase inhibitors (CDKI), p15, p16, p18, and p19, have a similar biochemical function in G1 cell cycle arrest, affecting RB1 family members, as demonstrated in vitro (Ruas and Peters, 1998; Sherr, 2001) . These proteins bind to early G1 cyclin-dependent kinases (cdk) 4 or 6 and prevent their interaction with D cyclins. Although their activities are similar, they have different physiological roles in vivo. An important function of one member, p15
Ink4b
, in hematopoietic cells of the myeloid lineage is to promote growth arrest in response to cytokines. This actvity is often associated with granulocyte/macrophage differentiation (Amanullah et al., 2000; Teofili et al., 2000) . In human acute myeloid leukemia (AML), the gene encoding p15
Ink4b , located on chromosome 9, is frequently hypermethylated within its 5 0 CpG island (Drexler, 1998; Cameron et al., 1999b) . Since hypermethylation is an epigenetic change known to result in downregulation of gene expression at the transcriptional level, this event is consistent with the inactivation of its function in growth arrest (Drexler, 1998; Jones and Laird, 1999) . Interestingly, this gene is rarely deleted or mutated in AML, although it is often deleted in acute lymphocytic leukemia (ALL) (Drexler, 1998) . Furthermore, another INK4 member, p16 Ink4a , which has an important tumor-suppressor role in many types of solid tumors is seldom inactivated in AML (Chin et al., 1998) . To date, there have not been any animal models that would support the role of p15
Ink4b as a tumor suppressor in myeloid leukemia and that would provide a system for investigating the role of this cdk inhibitor in AML. A mouse strain defective for p15 Ink4b was recently obtained by deletion of its second coding exon (Latres et al., 2000) . Mice with loss of this gene showed signs of extramedullary hematopoiesis and a low but reproducible incidence (8%) of angiosarcomas. Since hypermethylation of the Ink4b gene is so frequently associated with AML in man, we wanted to develop animal models that would demonstrate its tumor-suppressor activity. Here, we show that AMLs induced by a murine retrovirus MOL4070ALTR have hypermethylation of the 5 0 end CpG island of the Ink4b gene. Additionally, we demonstrate that p15
Ink4b deficiency enhances susceptibility to retrovirus-induced AML.
Results

Hypermethylation of the InK4b promoter in murine myeloid leukemias
It was previously reported that the 5 0 end of the murine Ink4b (Cdkn2b) gene contains a CpG island and most of the CpG dinucleotides are concentrated in a region spanning 800 bp and including exon 1 and part of intron 1 (Malumbres et al., 1997) . In the present study, this region of DNA in murine retrovirus-induced AML was examined for the presence of methylated C's. The leukemias that were used in the study were induced with a recently developed retrovirus, MOL4070LTR, which is capable of infecting all strains of mice and was shown to induce a high incidence of myeloid as well as lymphoid disease . It was constructed by placing most of the U3 portion of the long-terminal repeat (LTR) of the 4070A virus in a Moloney MuLV background. When inoculated intraperitoneally into newborn FVB and BALB/c mice, the virus produced 55 and 36% myeloid disease, respectively . These AML are predominantly myelomonocytic, as defined by a recent classification (Kogan et al., 2002) . To determine the extent of methylation of the CpG island in the promoter of MOL4070LTR-induced myeloid leukemias, DNA from these leukemias was subjected to a bisulfite sequencing procedure. Following bisulfite treatment, a 710 bp fragment was amplified, cloned, and sequenced. This area contains 61 CpGs that could potentially contain methylated Cs. Figure 1 depicts the location of methylated Cs in four primary myeloid leukemias induced by MOL4070LTR in BALB/c. Two of the four had methylated Cs throughout the entire region. One of these, 58B-11, had a high density of methylated CpGs in 10 individual clones, indicating that both alleles were hypermethylated, whereas the other one, 58B-12, had a high density of methylated CpGs in only five out of 11 clones, indicating that only one allele was hypermethylated. Two other leukemias, that were not demonstrated to have hypermethylation as primary neoplasms, developed methylation during transplantation (58B-2, 58B-6). To determine the overall proportion of leukemias with hypermethylation in the primary state, DNA's from 17 primary leukemias were examined Ink4b inactivation and myeloid leukemia L Wolff et al by methylation-specific PCR (MSP). The DNA was bisulfite treated and then amplified with primer pairs specific for unmethylated DNA or for methylated DNA. The results are depicted in Figure 2 . The reliability of the assay is evident from a correlation between the findings in Figure 2 and those in Figure 1 . For example, the methylated primers produced positive results for leukemias 58B-11 and 58B-12, which were demonstrated by sequencing to have Ink4b promoter methylation in the primary state of the leukemia. In addition, these primers were unable to produce amplified products from the DNA of leukemias 58B-2 and 58B-6 that were not shown to have methylation by the sequencing procedure. Overall, nine of 17 (53%) of the primary leukemias were positive for hypermethylation of the Ink4b CpG island (Figure 2 ).
Correlation between hypermethylation of the Ink4b locus and decreased mRNA expression
In order to determine if there was loss of Ink4b mRNA expression as a result of hypermethylation in the myeloid leukemias, total RNA was isolated from leukemic spleen and analysed by real-time PCR using the TaqMan assay, as shown in Figure 3 . The M1 cell line treated with IL-6 for 24 h was used as a positive control, because the Ink4b transcription is upregulated in response to this cytokine, and spleen cells from a mouse with homozygous deletion of Ink4b were used as a negative control (see below). Real-time PCR analysis of mRNA from the primary leukemia 58B-11, which had high levels of methylation on both alleles of the Ink4b gene, revealed an extremely low level of Ink4b expression. We compared the expression in leukemia 58B-2 before and after transplantation, since it changed from being unmethylated to methylated during the transplantation process. There was an obvious decrease in the expression, which correlated with increased methylation of the CpG island ( Figure 3 ). We noted that the level of expression in the unmethylated primary leukemia was not as high as that in the IL-6-treated M1 cells. This is not surprising since, first, the leukemic cells are not treated with cytokine prior to the assay and, second, the leukemias may have reduced expression of mRNA for p15 Ink4b due to Ink4b inactivation by other oncogenic mechanisms. We also found an inverse correlation between the degree of methylation and mRNA expression by real-time reverse transcription (RT)-PCR when comparing the primary and the transplant of leukemia 58B-12 (data not shown). Primary 58B-12 had hypermethylation on one allele (see Figure 1 ) and the first-generation transplant had hypermethylation on both alleles.
A correlation between methylation status and expression was also evident when a cell line, highly methylated at the Ink4b locus, was treated with a methylation inhibitor and these experimental data are presented in Figure 4 . The cell line 58B-2, which was established from the first-generation transplant, was shown to be hypermethylated on both alleles. It was treated with the methylation inhibitor 5-aza-2 0 deoxycytidine (Aza-dC) Figure 2 Hypermethylation in FVB and BALB/c myeloid leukemias, as determined by MSP analysis. Genomic DNA from MOL4070LTR-induced myeloid leukemias was sodium bisulfite treated and subjected to MSP. Leukemia designations beginning with 57 are from FVB mice and those beginning with 58B are from BALB/c mice. PCR products were electrophoresed on a 4% agarose gel. M, PCR results obtained with methylation-specific primers; U, PCR results obtained with primers specific for unmethylated DNA Figure 3 Real-time PCR analysis of p15 Ink4b mRNA expression in leukemias and leukemic cell lines. The TaqMan procedure was utilized to compare expression in cells that had either hypomethylation or hypermethylation of the Ink4b 5 0 CpG island. Total RNA was analysed from leukemias 58B-11 and 58B-2. Tissues were spleens of primary (11) or transplanted (Tp) leukemias. The positive and negative controls were RNA from M1 cells treated with IL-6 for 24 h and splenic tissue from a mouse with homozygous targeted deletion of Ink4b (KO), respectively. In this figure, the Ink4b KO control is too low to be visualized on the graph. Expression of rRNA by real-time PCR was used as a control to show that equal amounts of RNA were analysed in the experiment p15
Ink4b inactivation and myeloid leukemia L Wolff et al for 48 h and, as shown in Figure 4 , p15Ink4b mRNA expression increased substantially following this treatment. Since it had been reported elsewhere that trichostatin A (TSA), an inhibitor of histone deacetylases, can be synergenic with methylation inhibitors (Cameron et al., 1999a) , we added TSA for the last 12 h. In this case, the expression was increased slightly above treatment with Aza-dC alone.
Increased susceptibility to myeloid leukemia in mice with targeted deletion of the gene encoding p15
Ink4b
Since the murine AML presented here were shown to have hypermethylation of the Ink4b promoter and it was previously reported that murine T-cell lymphomas induced by g or neutron irradiation had a high incidence of hypermethylation of this locus (Malumbres et al., 1997) , we reasoned that targeted deletion of this gene might increase the susceptibility of mice to myeloid and/ or lymphoid leukemia. Furthermore, since mice in previous studies did not develop leukemia following targeted deletion alone (Latres et al., 2000) , we inoculated the animals as neonates with retrovirus, which was predicted to provide the second hit required for development of leukemia in the lifespan of the mice. ES cells were prepared at the National Cancer Institute by replacing exon 2 with the neo marker, using the targeting vector reported previously (Latres et al., 2000) . Chimeras, resulting from microinjection of ES cells into C57BL/6 blastocysts, were crossed with C57BL/6 mice. Offspring, heterozygous for the mutant allele, were mated with each other to generate wild-type ( þ / þ ), heterozygous ( þ /À), and homozygous (À/À) genotypes. A lack of expression of mRNA for p15
Ink4b in the spleen of a Ink4b (À/À) mouse and reduced expression in the spleen of a Ink4b ( þ /À) mouse is depicted in Figures 5. For this experiment, samples were untreated or treated with TGFb and RNA was detected using RT-PCR. TGFb had been previously shown to increase the expression of p15
Ink4b in epithelial cells (Hannon and Beach, 1994) . We also show here that TGFb increases the expression of this gene in spleen cells. Newborn offspring were injected intraperitoneally with retrovirus MOL4070LTR and maintained for 12 months to observe the leukemia development. The virus was the same one used to generate the myeloid leukemias which were examined for hypermethylation as described above; however, wild-type mice with the C57BL/6-129sv background did not develop the high incidence of disease, as Ink4b RNA in the spleen tissue of mixed 129/Sv-C57BL/6 wildtype mice ( þ / þ ) or mice with targeted deletion, either heterozygous ( þ /À) or homozygous (À/À) for the Ink4b genotype. The spleen cells were untreated or treated with TGFb for 6 h prior to RNA extraction. b-actin was used as a control for the integrity and quantity of analysed samples Ink4b mRNA expression in 58B-2 leukemic cell line treated with an inhibitor of DNA methyltransferases Aza-dc alone or in conjunction with an inhibitor of histone deacetylases TSA. The real-time PCR analysis was used to analyse p15
Ink4b mRNA expression in the leukemic cell line 58B-2, following treatment with Aza-dC alone or in conjunction with TSA. The cell line was derived from a first-generation transplant of 58B-2. The positive and negative controls are the same as in Figure 2 p15
Ink4b inactivation and myeloid leukemia L Wolff et al observed in FVB and BALB/c mice. This is most likely due to the poor spread of virus observed by us and others in mice with a C57BL/6 background (Nazarov et al., 1994) . Experiments were performed in these mice, because the initial breeding of mice with the targeted allele was facilitated with C57BL/6 mice. Interestingly, this low background of disease induction was an advantage in this experiment because it allowed our detection of disease as a function of loss of p15 Ink4b as described below.
Three types of disease developed in mice with the targeted deletion, myeloid leukemia, T-cell lymphoblastic lymphoma, and histiocytic sarcoma (see Table 1 ). Incidences of T-cell lymphoblastic lymphoma and histiocytic sarcoma occurred at a low incidence, and there was no statistically significant difference among Ink4b genotypes. However, loss of one Ink4b allele significantly increased susceptibility to myeloid leukemia (see Table 1 and Figure 6 ). Myeloid disease developed in the Ink4b ( þ /À) mice with an incidence of 10 out of 61 inoculated mice (16%). The result of the Fisher's exact test with a one-sided P-value was 0.029. Although the Ink4b (À/À) mice developed disease with a shorter average latency than Ink4b ( þ /À) mice (27 vs 38 weeks), the incidence was not increased compared to that of Ink4b ( þ /À) mice, as might be predicted by the complete loss of a tumor-suppressor gene. These results suggest, but do not prove, therefore, that the loss of p15
Ink4b may have both positive and negative effects on myeloid cells destined to become leukemias.
The myeloid diseases that developed in the Ink4b ( þ /À) mice were myelomonocytic (43%) or myeloid with maturation to the granulocyte lineage (57%). These were classified according to the recently published Bethesda proposals for classification (Kogan et al., 2002) . The myelomonocytic neoplasms were positive for the granulocytic marker, myeloperoxidase, and the macrophage marker F4/80, and negative for the lymphocyte marker CD3. An example is presented in Figure 7a (Figure 7h-j) . In general, there was evidence of metastasis in multiple major organs, and were usually present at high numbers in the blood leukemic cells (see Figure 7b) .
To determine if leukemias from Ink4b ( þ /À) mice had lost the second wild-type allele by deletion, we performed a Southern blot analysis (Figure 8a ). This analysis could clearly distinguish between the wild-type allele and the targeted allele, based on fragment size. It was found that, in seven out of eight cases examined, the single wild-type allele was retained (Figure 8a ) along with the targeted allele. In order to see if the second allele was hypermethylated, which would indicate that it was inactivated, we examined the DNAs by MSP. We found that six of the seven leukemias, which retained the wild-type allele, had evidence of methylation within the promoter (Figure 8b ). For three of these, the amount of DNA in PCR product was considerably less abundant than for the other three. Since the unmethylated product was abundant in all cases, this may indicate that only a portion of the tumor cells had undergone hypermethylation of the locus.
We also analysed leukemias from the Ink4b ( þ /À) mice for expression of p15
Ink4b mRNA by real-time PCR, and the results are depicted in Figure 9 . Expression in the myeloid leukemias, which were generated in the Ink4b ( þ /À) mice, was compared to that in other types of neoplasms generated in the study, namely, lymphoid leukemias and histiocytic sarcomas. All of the data presented in Figure 9 were prepared in the same experiment and can be compared directly, and panels (a) and (b) were separated for better visualization of the differences in RNA expression in the myeloid leukemias (panel (a)) and the other neoplasms (panel (b)). We found that the mRNA expression in the myeloid leukemias was lower than that in the lymphoid leukemias or the histiocytic sarcomas. None of the myeloid leukemias had expression above the threshold, whereas all of the other leukemias had expression above the threshold. The negative control data for the experiment (RNA from the spleen of a Ink4b null mouse, KO) were too low to be seen on the graph. Similarly, RNA from 10,162, which had loss of the second Ink4b allele, could not be detected. These data indicate that, for myeloid leukemia development, complete loss of p15
Ink4b expression is an advantage.
Analysis of the p53 pathway in leukemias induced in Ink4b ( þ /À) mice
Experimental evidence from studies on human AML indicate that inactivation of the CDKI p15 Ink4b by hypermethylation is important for leukemia development. This is because p15
Ink4b inhibits the phosphorylation of pRB and G1-S progression. Our data suggest that inactivation of the pRb pathways is also an important event in murine AML. Since another cell cycle arrest pathway, the p53 pathway, has been proposed to be inactivated in most cancers, we analysed for the expression of p53 by western analysis. The 2-1-8 macrophage cell line derived in previous experiments in our laboratory was used as a positive control and the M1 myeloblastic cell line was used as a negative control. As shown in Figure 10a , the leukemias did not express p53 protein. Interestingly, Mdm2 was expressed in all of the leukemias, although the expression was very weak in 10 161. Mdm2 expression may account for the lack of p53, because it degrades p53 by a ubiquitin-dependent process. p19
Arf , known to inhibit Mdm2-dependent degradation, was not expressed in these leukemias as determined by an RT-PCR assay (Figure 10b ), although the genomic DNA from this locus was present.
Discussion
This study shows that loss of p15
Ink4b promotes the development of murine AML. This was evident from two types of observations presented here. First hypermethylation of the locus occurs in murine leukemias of this lineage and this methylation is inversely correlated with expression of the gene at the mRNA level. This mimics events that occur in human AML because hypermethylation of this locus was found to occur with high frequency in these leukemias (reviewed in Drexler, 1998) . Second, we show that mice with p15 Ink4b deficiency are more susceptible to retrovirus-induced myeloid leukemia. The incidence for myeloid disease in mice with loss of two alleles was clearly lower than that for the heterozygous genotype. Therefore, there may be opposing effects due to the loss of p15
Ink4b in the mice. One mechanism could be pro-tumor formation, while the other may inhibit tumor development. The tumor-opposing effect could be intrinsic to the cells or be caused by the myeloid cell microenvironment. Further studies will be required to explain the results in the p15
Ink4b null mice. The development and characterization of a conditional knockout mouse, for example, may lead to a delineation of specific events caused by the loss of p15
Ink4b
.
Our data and that of Latres et al. (2000) demonstrate that p15
Ink4b is a rather weak tumor suppressor. Interestingly, it was similarly found that loss of p16 Ink4a has a mild tumor-suppressor phenotype by itself (Krimpenfort et al., 2001; Sharpless et al., 2001) . However, when loss of p16
Ink4a was combined with heterozygous loss of the gene encoding p19
Arf and a single dose of 7,12-dimethylbenzanthracene (DMBA), it confers susceptibility to metastatic melanoma in mice (Krimpenfort et al., 2001 ). p19
Arf is part of a different pathway of growth control involving p53. These data by Krimpenfort and co-workers provide additional evidence that inactivation of Ink4 CDKI genes must be combined with other oncogenic events to observe susceptibility to specific neoplastic diseases. In contrast to the targeted deletion of p15
Ink4b or p16
Ink4a
, targeted deletion of the gene which encodes p19
Arf from alternate exons within the INK4 locus produces a high incidence of spontaneous tumors and, therefore, is a more potent tumor Ink4b in different types of neoplasms generated in this study. All of the data presented were prepared in the same experiment and can be compared directly. Panels (a) and (b) were separated for better visualization of the differences in RNA expression in the myeloid leukemias (panel (a)) and the other neoplasms, lymphoblastic leukemias and histiocytic sarcomas (panel (b) ). The negative control data for the experiment (RNA from the spleen of a Ink4b null mouse, KO) were too low to be seen on the graph. Similarly, RNA from 10 162, which had loss of the second Ink4b allele, could not be detected. The legends show the animal number and type of leukemia. Expression of rRNA by real-time PCR was used as a control to show that equal amounts of RNA were analysed in the experiment p15
Ink4b inactivation and myeloid leukemia L Wolff et al suppressor in mice (Kamijo et al., 1997) . p19
Arf promotes growth arrest and apoptosis through the p53 pathway. It stabilizes p53 by preventing Mdm2-induced degradation (Ryan et al., 2001) . In another study, we have found that p19
Arf is often deleted in murine myeloid leukemias (Haviernik et al., 2003) . Inactivation of the p53 pathway may be important in murine myeloid leukemia, because p53 was not expressed in myeloid leukemias in this study. Interestingly, common mechanisms of reducing the activity of this pathway in human AML are p53 mutations and MDM-2 overexpression (Stirewalt and Radich, 2000) .
The retrovirus was presumed to provide oncogenic events that allowed the development of myeloid leukemia in p15 Ink4b -deficient mice. Interestingly, there were a low number of integrated proviruses in these leukemias. Although myeloid leukemias induced by MOL4070LTR in BALB/c and FVB mice contain an average of about 7.5 integrated proviruses per neoplasm, leukemias induced by the same virus in the mice deficient for p15
Ink4b have nearly half the number of proviruses (average of 4) unpublished data.
Although we have shown here that the Ink4b locus is hypermethylated in retrovirus-induced myeloid leukemia, previously, we found cases of murine myeloid leukemia in which the gene was not found to be hypermethylated. These were specific subsets of leukemia that were mature monocytic/macrophage tumors induced by deregulated expression of either the oncogene c-myc or c-myb. At the conclusion of these studies, it was proposed that c-Myc is capable of overriding the inhibitory effects of p15
Ink4b on the cell cycle (Haviernik et al., 2003) . On the other hand, c-Myb is involved, at least indirectly, in the inhibition of p15 Ink4b expression at the transcriptional level . Interestingly, for c-Myb, this may be one of several ways through which it promotes proliferation in cells of the myeloid lineage (Schmidt et al., 2000; Wolff et al., 2001) . Although many of the leukemias induced by MOL4070LTR in BALB/c and FVB mice were shown to have hypermethylation of Ink4b, there was a subset that lacked hypermethylation at the Ink4b locus. When the latter were examined for rearrangements of c-myb or c-myc, no rearrangments were observed (unpublished data.). This ruled out the possibility that overexpression of one of these genes could bypass the need for hypermethylation.
This investigation demonstrates that murine models involving inactivation of the Ink4b locus can be established. These models can be further developed in the future to provide in vivo systems for testing approaches to the reverse methylation of the Ink4b locus in leukemias and reduce their growth. In addition, they can be utilized to test whether reactivation of the p15
Ink4b gene expression inhibits leukemia progression.
Materials and methods
Retrovirus-induced leukemia
A retrovirus called MOL4070LTR was used for leukemia induction; this virus was recently constructed using Moloney MuLV and amphotropic virus 4070A sequences . For virus production, 10 5 NIH3T3 cells, chronically infected with virus, were seeded in 100 mm dishes with an equal number of uninfected NIH3T3 cells. The cells were propagated for 4 days, the medium was replaced with fresh medium and, on day 5, the virus-containing medium was harvested and assayed in the XC assay (Rowe et al., 1970) . Newborn mice were inoculated intraperitoneally with 4 Â 10 4 infectious particles in 0.05 ml of culture medium. Mice were housed and cared for in accordance with the recommendations for the Guide For The Care And Use Of Laboratory Animals. They were routinely monitored for evidence of disease and moribund mice were euthanized by cervical dislocation. Tissues were fixed in Fekete's modification of Tellyesniczky's fluid (Fekete, 1938) , processed into paraffin, and stained with hematoxylin and eosin (H&E). Immunohistochemistry was also performed using the following antibodies: rabbit anti-CD3 (DAKO), rat anti-mouse F4/80 (Serotec), and rabbit anti-human myeloperoxidase (DAKO).
For leukemic cell transplantation, 10 4 cells were inoculated into the tail vein.
Cells and treatments
M1 cells were cultured and treated with IL-6 as previously described . The cell line 58B-2 was established from spleen cells from a generation one transplantrecipient mouse. The cell line was cultured in MyeloCultt H5100 medium (StemCell Technologies, Inc.) supplemented with 5 ng/ml murine granulocyte-macrophage-colony-stimulating factor (GM-CSF)(PeproTech, Inc.). For treatment with Aza-dC, 58B2 cells were split to low density, 14 h before treatment. They were then treated with Aza-dC (1 mM) alone for 48 h or cotreated for 48 h with Aza-dC (1 mM) and trichostatin (TSA) (165 nM), where TSA was added for only the last 12 h of treatment. After treatment, cells were washed in PBS and total RNA was isolated using the RNeasy Mini kit (Qiagen). Spleen cells were treated with human TGFb (PeproTech) at a concentration of 10 ng/ml in MyeloCultt H5100 medium.
Generation of mice with targeted deletion of Ink4b
The previously described Ink4b targeting vector pEL14 was electroporated into the CJ7 ES cell line (Tessarollo, 2001 ) and DNAs derived from G418/FIAU-resistant ES clones were screened by Southern analysis, as previously described (Latres et al., 2000) . Two independent targeted ES cell clones were injected into C57BL/6 blastocysts and they generated chimeras that transmitted the mutated allele to the progeny (Bonin et al., 2001) . Breeding of two Ink4b heterozygous (À/ þ ) mice gave rise to homozygous mutant mice at a frequency of 25%. Mice were bred in a specific, pathogen-free facility with food and water ad libitum. Tail DNA was genotyped using two sets of primers described in Latres et al. (2000) , which determined the presence of the wild-type and targeted type alleles. Leukemia susceptibility studies were carried out in mice with a mixed 129/Sv-C57BL/6 background.
Bisulfite genomic sequencing
Determination of methylated CpGs by bisulfite genomic sequencing was carried out as described in Schmidt et al. (2001) . Amplification was carried out using the forward primer GAGATGAATTAGTTTTGTATGATAGATG and the reverse primer CAAAATTTTACTCTTACAAAACCTACCTC.
Methylation-specific PCR (MSP)
DNA methylation patterns were determined in some experiments by the MSP procedure (Herman et al., 1996) . Sodium bisulfite-treated DNA was amplified using primer pairs that were specific for either unmethylated DNA or methylated DNA. Primers were designed using a the MethPrimer program (Li and Dahiya, 2002) . To detect DNA that was unmethylated, the forward primer GGTTTTTTATTTGGTGTGAGTTGT and the reverse primer CTCTAAAAACCCAATAACTT-CAAT were used. To detect DNA that was methylated, the forward primer GTTTTTTATTCGGCGTGAGTC and the reverse primer CTCTAAAAACCCAATAACTTCGAT were used.
RT-PCR
Expression of mRNA for p15 Ink4b in mouse tissues was determined by RT and amplification using the total RNA prepared with an RNeasy mini kit (Qiagen). The Titan One Tube kit from Roche Diagnostics Corp. was used according to the manufacturer's instructions. RT-PCR was performed using 5 ng of total RNA. Primer sequences were as follows:
forward, GTTGGGCGGCAGCAGTGAC; reverse, CAATC TCCAGTGGCAGCGTG.
Real-time RT-PCR
Expression of p15
Ink4b mRNA was measured by a TaqManbase real-time RT-PCR. Primer and probe sequences were as follows: forward, AACGCCCTGAACCGCTTC; reverse, GCAGCAGCAGCTCTGCCA; and probe, 6FAM-AGGCG CCCAATCCAGGTCATGATG-TAMRA. The primers are from the end of exon 1 and the beginning of exon 2, and the probe overlaps the junction of the exons. RT and PCR amplification was carried out using TaqMan Universal Mastermix (PE Applied Biosystems). The assay was performed in a 96-well optical tray with a final reaction volume of 25 ml containing 12.5 ml of TaqMan Universal, 0.25 ml of forward (22.5 pmol) and reverse primers (7.5 pmol), 2 ml of the probe (2.5 mM), and 250 ng of total RNA. For control PCR amplification of 18S RNA, a kit from PE Applied Biosystems was utilized. Real-time PCR was performed in an ABI PRISM 7700 (PE Applied Biosystem).
Southern blot analysis
Genomic DNA was isolated using the DNeasy Tissue Kit (Qiagen). For Southern blot analysis, 10 mg of genomic DNA was digested with BamHI, separated on a 7% agarose gel, transferred onto a nylon membrane, and hybridized with random-priming labeled probes (Ready-To-Go, DNA-labeling Beads, Amersham Pharmacia Biotech). The probe used for the Ink4b locus was probe B, reported in Latres et al. (2000) .
Western analysis
Tumor tissues were grinded into powder in liquid nitrogen and lysed in ice-cold lysis buffer (20 mM Tris-HCl (pH 7.5), 50 mM NaCl, 0.5% Nonidet P-40, 0.5% SDS, and 0.5% sodium deoxycholate) supplemented with a mix of protease inhibitors (Completet, Boehringer Mannheim), supplemented with 1 mM PMSF. Lysates were sonicated for 30 s, cleared by centrifugation at 13 000 g for 15 min at 41C, and soluble proteins were fractionated by SDS-PAGE and transferred to a nitrocellulose membrane. Immunoblots were incubated either with mouse monoclonal anti-MDM2 (Oncogene Research Products) or rabbit polyclonal anti-p53 antibodies (Santa Cruz), and visualized with SuperSignal West Pico chemiluminiscent substrate (Pierce), according to the manufacturer's instructions.
